Here's Why Lexicon Pharmaceuticals Lost 28.8% in January




  • In Business
  • 2019-02-11 15:22:00Z
  • By Maxx Chatsko, The Motley Fool
 

What happened

Shares of Lexicon Pharmaceuticals (NASDAQ: LXRX) fell nearly 29% last month, according to data provided by S&P Global Market Intelligence. The company announced that its lead drug candidate, Zynquista, didn't muster a majority of support from an advisory committee at the U.S. Food and Drug Administration. The adjuvant therapy for type-1 diabetes didn't get outright rejected, either. Rather, the vote ended in a stalemate, with eight panelists seeing a net benefit, and the other eight panelists taking a more cautious approach.

That plunged the drug candidate's future into uncertainty -- taking the stock with it. Shares of Lexicon Pharmaceuticals had gained nearly 18% since the start of the year, until the advisory committee's impasse was reported. They tumbled nearly 39% from the day the news was reported to the end of the month.

Image source: Getty Images.

So what

The stalemate from the advisory committee doesn't necessarily seal the fate of Zynquista. Regulators at the FDA will ultimately decide whether or not the drug candidate will hit the market, although they typically take the panel's recommendation into consideration. Even then, the FDA could ask Lexicon Pharmaceuticals to conduct further study and collect more data. While that might delay the drug's potential market launch, it would be a better outcome than an outright rejection.

Wall Street analysts and investors will be watching. The drug was expected to have blockbuster potential (read: annual sales of $1 billion or more) if it received marketing approval as an adjuvant therapy in both type 1 and type 2 diabetes. Considering the company reported an operating loss of $91 million through the first nine months of 2018, adding such a high-potential commercial product to the portfolio would help alleviate concerns over the financial flexibility of the business.

Now what

Investors have suffered through a pretty rough stretch lately. Lexicon Pharmaceuticals stock peaked in July 2018 at nearly $13 per share, but shares currently trade at just under $5 apiece. While all is not lost for Zynquista, the new uncertainty regarding the next steps for the expected blockbuster will likely weigh on the stock for the foreseeable future.

Maxx Chatsko has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

COMMENTS

More Related News

3 Top Healthcare Stocks to Buy in April
3 Top Healthcare Stocks to Buy in April

GW Pharmaceuticals, Illumina, and Intercept Pharmaceuticals could all be great buys this month.

Why J.B. Hunt, Bank of America, and Boston Scientific Slumped Today
Why J.B. Hunt, Bank of America, and Boston Scientific Slumped Today

These three stocks fell as the broader market climbed.

FDA orders transvaginal surgical mesh pulled from market
FDA orders transvaginal surgical mesh pulled from market

The U.S. Food and Drug Administration on Tuesday ordered makers of transvaginal surgical mesh implants to immediately stop their sale and distribution in the United States, the latest action by the agency to tackle safety issues related to the devices. The FDA said Boston Scientific Corp and Coloplast A/S did not demonstrate a reasonable assurance of safety and effectiveness of these devices in their premarket applications. The companies will have 10 days to submit their plan to withdraw these products from the market, the FDA said in a statement https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm636114.htm.

The FDA
The FDA's New Sugar Label Could Seriously Reduce Heart Disease and Diabetes-And Boost Longevity

A new study from Tufts University finds just how beneficial an added sugar label can be for our health and our wallets.

1 Under-the-Radar Healthcare Stock Wall Street is Overlooking
1 Under-the-Radar Healthcare Stock Wall Street is Overlooking

This Israeli-based pharma company is poised to receive regulatory approval for its first product in the second half of 2019.

Leave a Comment

Your email address will not be published. Required fields are marked with *

Cancel reply

Comments

Top News: Business

facebook
Hit "Like"
Don't miss any important news
Thanks, you don't need to show me this anymore.